Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

NCT00520481 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG: IMC-A12 (Cixutumumab)

Sponsor

Eli Lilly and Company